Our Top Picks
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have reshaped medical weight management. Clinical trials show average weight loss of 15–22% over 68–72 weeks when combined with lifestyle support. The challenge for most patients isn't whether these drugs work. It's navigating a fragmented telehealth market where pricing, medication sourcing, and clinical oversight vary wildly.
The first fork in the road is compounded vs. brand-name medication. Compounded semaglutide and tirzepatide are prepared by licensed pharmacies when brand-name drugs are in shortage or when a prescriber deems it medically appropriate. They're typically far cheaper — often $89–$199 per month versus $1,000–$1,350 for brand-name Wegovy without insurance. The trade-off: compounded products aren't FDA-approved finished drugs, quality depends on the compounding pharmacy, and formulations can differ between providers.
Brand-name GLP-1s prescribed through telehealth platforms are the same medications you'd get from a local clinic, with manufacturer oversight and established safety data. Insurance coverage remains inconsistent — roughly 40% of employer plans now cover obesity medications, but prior authorization requirements are strict. Cash-pay brand-name pricing through telehealth typically runs $999–$1,349 per month.
Our team — including a registered dietitian, an obesity medicine physician, and two health policy researchers — spent three months evaluating 14 telehealth GLP-1 platforms. We completed intake flows anonymously, verified prescriber credentials, compared all-in monthly costs at standard starting doses, assessed coaching and follow-up protocols, and reviewed pharmacy sourcing for compounded products. Ro earned our top spot for balancing transparent pricing, board-certified prescriber access, and a clear path to both compounded and brand-name options.
In this guide
1. Ro — Best overall
Ro (formerly Roman)
Ro's Body Program is the most complete telehealth GLP-1 experience we tested. Intake is handled by licensed physicians (not nurse practitioners only), compounded semaglutide ships from Ro-affiliated 503B pharmacies with published sourcing, and patients who qualify for brand-name Wegovy or Zepbound can transition without switching platforms. Ongoing check-ins are built into the subscription — not billed as add-ons. The app tracks weight, side effects, and dose titration with unusual clarity for a telehealth product.
2. Hims — Best for bundled care
Hims & Hers Weight Loss
Hims packages GLP-1 prescribing inside a broader telehealth ecosystem — metabolic labs, protein supplements, and ongoing messaging with a care team are included in the monthly fee rather than sold à la carte. Compounded semaglutide is the default cash-pay option; brand-name prescriptions are available where clinically indicated. The onboarding flow is the fastest we tested (under 12 minutes), though the bundled model means you're paying for services you may not use.
3. Henry Meds — Best value compounded
Henry Meds
Henry Meds built its reputation on aggressive compounded pricing — and it still undercuts most competitors on a per-milligram basis. A three-month supply of compounded semaglutide at starting dose runs roughly $297 ($99/month effective), with dose increases priced incrementally rather than jumping to a new tier. Clinical support is lighter than Ro or Found: asynchronous provider messaging is included, but there's no structured coaching program. The right pick if your priority is lowest cash-pay medication cost and you already have dietary support elsewhere.
4. Found — Best coaching support
Found
Found treats GLP-1 medication as one piece of a broader obesity-care model. Every member is matched with a health coach who conducts weekly check-ins, and the platform uses a proprietary metabolic assessment to tailor medication and lifestyle recommendations. Compounded semaglutide is available at competitive rates; brand-name options are offered where appropriate. The coaching quality was the highest we encountered — coaches are trained in motivational interviewing and obesity-specific behavior change, not generic wellness scripting.
5. Calibrate — Best metabolic program
Calibrate
Calibrate's One-Year Metabolic Reset is the most structured program on this list. It combines GLP-1 prescribing with a curriculum covering nutrition, sleep, exercise, and emotional health — each pillar has measurable targets reviewed in biweekly coaching sessions. Medication is typically brand-name (insurance billing attempted first) with compounded fallback. The premium price reflects the program intensity: this is closer to a metabolic clinic than a prescription delivery service.
6. Mochi Health — Best for custom dosing
Mochi Health
Mochi Health differentiates on prescribing flexibility. Physicians can customize compounded semaglutide and tirzepatide concentrations, adjust titration timelines outside standard protocols, and coordinate combination approaches (e.g., GLP-1 plus metformin) within a single platform. This matters for patients who plateau on standard dosing or experience side effects that require slower ramp-up. Pricing sits between Henry Meds and Ro, and clinical messaging response times averaged under four hours in our testing.
Side-by-side comparison
| Provider | Medication | Prescriber | Rating | $/month | Coaching | |
|---|---|---|---|---|---|---|
| Ro | Compounded or brand | MD/DO | ★★★★★ 4.7 | $145 | Included | View |
| Hims | Compounded or brand | NP / MD | ★★★★☆ 4.5 | $199 | Bundled | View |
| Henry Meds | Compounded | NP-led | ★★★★☆ 4.3 | $99 | Minimal | View |
| Found | Compounded or brand | MD/DO | ★★★★☆ 4.4 | $149 | Weekly | View |
| Calibrate | Brand preferred | MD/DO | ★★★★☆ 4.2 | $199+ | Biweekly | View |
| Mochi Health | Custom compounded | MD/DO | ★★★★☆ 4.1 | $119 | Async | View |
| Eden | Compounded | NP-led | ★★★☆☆ 3.9 | $169 | Minimal | View |
How we tested
Our 3-month evaluation covered 14 telehealth GLP-1 platforms. Each was scored across six weighted criteria: prescriber credentials and accessibility (25%), medication sourcing and transparency (20%), all-in monthly cost at standard starting dose (20%), clinical follow-up and coaching quality (15%), platform usability and state availability (10%), and patient review sentiment (10%).
We completed anonymous intake flows in 12 states, verified pharmacy licenses for compounded sourcing, and requested written confirmation of 503A/503B pharmacy relationships from each provider. Three platforms were excluded from the ranking due to undisclosed pharmacy sourcing or prescriber credential gaps. Full methodology and pricing snapshots are available in our research library.
Important: This article is for informational purposes and does not constitute medical advice. GLP-1 medications carry risks including nausea, pancreatitis, and thyroid C-cell tumor concerns (boxed warning for semaglutide and tirzepatide). They are not appropriate for everyone. Always consult a licensed physician before starting any weight-loss medication, and never purchase GLP-1 products from unregulated sources.
Frequently asked questions
Compounded vs. brand-name semaglutide — which should I choose?
Brand-name Wegovy and Ozempic have the most extensive FDA-reviewed safety and efficacy data. Compounded semaglutide is a legitimate option when prescribed by a licensed clinician and prepared by a licensed 503A or 503B pharmacy — typically at 60–85% lower cost. The key variables are pharmacy quality, concentration accuracy, and whether your provider discloses sourcing. If you have insurance coverage for brand-name GLP-1s, that path is usually preferable. If you're paying cash, compounded through a reputable telehealth platform is the pragmatic choice for most patients.
How much do telehealth GLP-1 programs actually cost?
As of May 2026, cash-pay compounded semaglutide through telehealth ranges from roughly $89–$199 per month at starting doses, depending on provider and supply length. Brand-name Wegovy or Zepbound through telehealth typically costs $999–$1,349 per month without insurance. Program fees (coaching, labs, platform access) add $0–$199 on top of medication at some providers. Dose increases raise compounded costs incrementally; brand-name pricing is flat regardless of dose.
Do I actually talk to a doctor, or just fill out a form?
It varies significantly. Every legitimate platform requires a clinical intake reviewed by a licensed prescriber before medication is dispensed — but the depth of interaction ranges from a 5-minute async questionnaire (Henry Meds) to a 30-minute video visit (Calibrate). Ro, Found, and Mochi Health all provide direct physician messaging. We recommend choosing a platform where you can reach your prescriber within 24 hours if side effects or dosing questions arise.
Will my insurance cover GLP-1 weight-loss medication?
Coverage improved in 2025–2026 but remains inconsistent. Roughly 40% of large employer plans now cover anti-obesity GLP-1 medications, often with BMI thresholds (≥30, or ≥27 with comorbidities) and prior authorization requiring documented lifestyle intervention attempts. Medicare still does not cover weight-loss medications. Platforms like Calibrate and Found offer insurance navigation; most compounded-focused providers are cash-pay only.
Are compounded GLP-1 medications safe?
Compounded medications are not FDA-approved finished products, but they are legal when prepared by licensed pharmacies in response to a valid prescription during a recognized drug shortage or for a specific patient need. Safety depends on pharmacy quality controls — insist on 503B outsourcing facility sourcing when possible, and avoid any provider that won't disclose their compounding pharmacy. Reported risks mirror brand-name GLP-1s (GI side effects, rare pancreatitis) plus potential concentration variability if pharmacy standards are poor.
Sources & references
- Wilding, J. P. H. et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021.
- Jastreboff, A. M. et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022.
- U.S. Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." FDA Consumer Update, 2024.
- American Diabetes Association. "Standards of Care in Diabetes — Obesity and Weight Management." Diabetes Care, 2026.
- Kaiser Family Foundation. "Employer Coverage of GLP-1 Agonists for Weight Loss." KFF Issue Brief, 2025.